XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.1
RESTRUCTURING
 12 Months Ended
Apr. 02, 2022
Restructuring and Related Activities [Abstract]  
RESTRUCTURING RESTRUCTURINGOn an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.
In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During the first quarter of fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The Company now expects to incur aggregate charges between $95 million and $105 million by the end of fiscal 2025. The majority of charges will result in cash outlays, including severance and other employee costs, and will be incurred as the specific actions required to execute these initiatives are identified and approved. During fiscal 2022, 2021 and 2020 the Company incurred $28.7 million, $15.1 million and $11.9 million of restructuring and restructuring related costs under this program, respectively. Total cumulative charges under this program are $55.7 million as of April 2, 2022.

The following table summarizes the activity for restructuring reserves related to the 2020 Program and prior programs for the fiscal years ended April 2, 2022, April 3, 2021 and March 28, 2020, substantially all of which relates to employee severance and other employee costs:
(In thousands)2020 ProgramPrior ProgramsTotal
Balance at March 31, 2019$— $7,479 $7,479 
Costs incurred, net of reversals2,234 1,357 3,591 
Payments(1,098)(7,177)(8,275)
Non-cash adjustments— (147)(147)
Balance at March 28, 2020$1,136 $1,512 $2,648 
Costs incurred, net of reversals1,501 (57)1,444 
Payments(2,062)(1,018)(3,080)
Balance at April 3, 2021$575 $437 $1,012 
Costs incurred, net of reversals4,202 28 4,230 
Payments(2,317)(120)(2,437)
Balance at April 2, 2022$2,460 $345 $2,805 

The following presents the restructuring costs by line item during fiscal 2022, 2021 and 2020 within our accompanying consolidated statements of income and comprehensive income:
(In thousands) 202220212020
Cost of goods sold$2,236 $390 $1,082 
Research and development105 142 532 
Selling, general and administrative expenses1,889 912 1,977 
Total$4,230 $1,444 $3,591 

As of April 2, 2022, the Company had a restructuring liability of $2.8 million, of which approximately $2.5 million is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $24.6 million, $14.2 million and $16.3 million in fiscal 2022, 2021 and 2020, respectively, that do not constitute restructuring costs under ASC 420, Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions and include program management costs associated with the implementation of outsourcing initiatives and recent accounting standards.
The following presents the restructuring related costs by line item during fiscal 2022, 2021 and 2020 within our accompanying consolidated statements of income and comprehensive income:
(In thousands) 202220212020
Cost of goods sold$17,832 $9,318 $2,227 
Research and development714 1,026 354 
Selling, general and administrative expenses6,048 3,873 13,706 
Total$24,594 $14,217 $16,287 

The tables below present restructuring and restructuring related costs by reportable segment:
Restructuring costs
(In thousands) 202220212020
Plasma$2,492 $454 $544 
Blood Center(18)201 (5)
Hospital(93)322 845 
Corporate1,849 467 2,207 
Total$4,230 $1,444 $3,591 
Restructuring related costs
(In thousands) 202220212020
Plasma$7,906 $1,870 $820 
Blood Center556 1,599 320 
Hospital379 14 — 
Corporate15,753 10,734 15,147 
Total$24,594 $14,217 $16,287 
Total restructuring and restructuring related costs$28,824 $15,661 $19,878